GZGI Trial: Orforglipron in Obesity

GZGI TRIAL Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity Phase 2, randomized, double-blind, placebo-controlled trial Objective:To assess the efficacy and safety of orforglipron, an oral non-peptide GLP-1 receptor agonist, for weight reduction in adults with obesity, or … Read More

STEP-HFpEF DM: Semaglutide in HFpEF and DM

The study suggests that Semaglutide is effective in reducing symptoms and weight in patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes when compared to a placebo

SELECT Trial: Semaglutide and CV outcomes

Semaglutide Improve CV events? SELECT Trial Summary The SELECT trial, a pivotal study published in the New England Journal of Medicine (NEJM) in November 2023, has offered the medical community valuable insights into the treatment of cardiovascular (CV) events in … Read More